

# **Epiomic Epidemiology Series: Venous Thromboembolism Forecast in 24 Major Markets 2018–2028**

<https://marketpublishers.com/r/EFF9BFB7DC8EN.html>

Date: July 2018

Pages: 78

Price: US\$ 5,800.00 (Single User License)

ID: EFF9BFB7DC8EN

## **Abstracts**

**Black Swan Analysis Epiomic Epidemiology Series Forecast Report on Venous Thromboembolism in 24 Major Markets**

Venous thromboembolism (VTE) is a disease in which thrombi or blood clots form in venous blood vessels and either remain at their site of origin or move with the blood flow until they reach a vessel with a diameter small enough to form an occlusion. Clots formed in the large limb or pelvic veins cause a clinical manifestation of VTE called deep vein thrombosis (DVT), while emboli (detached clot fragments) which move to and cause obstruction of pulmonary blood vessels cause a pulmonary embolism (PE). VTE is the third most common cardiovascular disease worldwide (after myocardial infarction and ischaemic stroke), with 2–5% of the global population affected throughout their lives.

This report provides the current prevalent population for VTE across 24 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Norway, Sweden, Denmark, Finland, Austria, Portugal, Greece, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, DVT and PE patient subsets, as well as those with the main co-morbidities, have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for VTE include:

Cancer

Inflammatory bowel disease

Obesity

Cardiovascular diseases

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

Ability to quantify patient populations in global VTE market to target the development of future products, pricing strategies and launch plans.

Further insight into the prevalence of the subdivided types of VTE and identification of patient segments with high potential.

Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.

Better understanding on the impact of specific co-morbid conditions on the prevalent population of VTE patients.

Identification of VTE patient sub-populations that require treatment.

Better understanding of the specific markets that have the largest number of VTE patients.

## **Contents**

**INTRODUCTION**

**CAUSE OF THE DISEASE**

**RISK FACTORS & PREVENTION**

**DIAGNOSIS OF THE DISEASE**

**VARIATION BY GEOGRAPHY/ETHNICITY**

**DISEASE PROGNOSIS & CLINICAL COURSE**

**KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE**

**METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS**

**TOP-LINE PREVALENCE FOR VENOUS THROMBOEMBOLISM**

**DEEP VEIN THROMBOSIS**

**PULMONARY EMBOLISM**

**COMORBIDITIES OF VENOUS THROMBOEMBOLISM PATIENTS**

**ABBREVIATIONS USED IN THE REPORT**

**OTHER BLACK SWAN SERVICES & SOLUTIONS**

**REPORTS & PUBLICATIONS**

**ONLINE EPIDEMIOLOGY DATABASES**

**ONLINE PHARMACEUTICAL PRICING DATABASE**

**REFERENCES**

## APPENDIX

## List Of Tables

### LIST OF TABLES AND FIGURES

Table 1. VTE risk factors

Table 2. Prevalence of VTE, total (000s)

Table 3. Prevalence of VTE, males (000s)

Table 4. Prevalence of VTE, females (000s)

Table 5. Prevalence of DVT, total (000s)

Table 6. Prevalence of DVT, males (000s)

Table 7. Prevalence of DVT, females (000s)

Table 8. Prevalence of PE, total (000s)

Table 9. Prevalence of PE, males (000s)

Table 10. Prevalence of PE, females (000s)

Table 11. VTE patients with post-thrombotic syndrome, total (000s)

Table 12. VTE patients with venous ulcers, total (000s)

Table 13. VTE patients with major bleeding from prophylaxis, total (000s)

Table 14. PE patients with chronic thromboembolic pulmonary hypertension, total (000s)

Table 15. Abbreviations and acronyms used in the report

Table 16. USA prevalence of venous thromboembolism by 5-yr age cohort, males (000s)

Table 17. USA prevalence of venous thromboembolism by 5-yr age cohort, females (000s)

Table 18. Canada prevalence of venous thromboembolism by 5-yr age cohort, males (000s)

Table 19. Canada prevalence of venous thromboembolism by 5-yr age cohort, females (000s)

Table 20. France prevalence of venous thromboembolism by 5-yr age cohort, males (000s)

Table 21. France prevalence of venous thromboembolism by 5-yr age cohort, females (000s)

Table 22. Germany prevalence of venous thromboembolism by 5-yr age cohort, males (000s)

Table 23. Germany prevalence of venous thromboembolism by 5-yr age cohort, females (000s)

Table 24. Italy prevalence of venous thromboembolism by 5-yr age cohort, males (000s)

Table 25. Italy prevalence of venous thromboembolism by 5-yr age cohort, females (000s)

Table 26. Spain prevalence of venous thromboembolism by 5-yr age cohort, males (000s)

Table 27. Spain prevalence of venous thromboembolism by 5-yr age cohort, females (000s)

Table 28. UK prevalence of venous thromboembolism by 5-yr age cohort, males (000s)

Table 29. UK prevalence of venous thromboembolism by 5-yr age cohort, females (000s)

Table 30. Poland prevalence of venous thromboembolism by 5-yr age cohort, males (000s)

Table 31. Poland prevalence of venous thromboembolism by 5-yr age cohort, females (000s)

Table 32. Norway prevalence of venous thromboembolism by 5-yr age cohort, males (000s)

Table 33. Norway prevalence of venous thromboembolism by 5-yr age cohort, females (000s)

Table 34. Sweden prevalence of venous thromboembolism by 5-yr age cohort, males (000s)

Table 35. Sweden prevalence of venous thromboembolism by 5-yr age cohort, females (000s)

Table 36. Denmark prevalence of venous thromboembolism by 5-yr age cohort, males (000s)

Table 37. Denmark prevalence of venous thromboembolism by 5-yr age cohort, females (000s)

Table 38. Finland prevalence of venous thromboembolism by 5-yr age cohort, males (000s)

Table 39. Finland prevalence of venous thromboembolism by 5-yr age cohort, females (000s)

Table 40. Austria prevalence of venous thromboembolism by 5-yr age cohort, males (000s)

Table 41. Austria prevalence of venous thromboembolism by 5-yr age cohort, females (000s)

Table 42. Portugal prevalence of venous thromboembolism by 5-yr age cohort, males (000s)

Table 43. Portugal prevalence of venous thromboembolism by 5-yr age cohort, females (000s)

Table 44. Greece prevalence of venous thromboembolism by 5-yr age cohort, males (000s)

Table 45. Greece prevalence of venous thromboembolism by 5-yr age cohort, females (000s)

Table 46. Turkey prevalence of venous thromboembolism by 5-yr age cohort, males (000s)

Table 47. Turkey prevalence of venous thromboembolism by 5-yr age cohort, females (000s)

Table 48. Japan prevalence of venous thromboembolism by 5-yr age cohort, males (000s)

Table 49. Japan prevalence of venous thromboembolism by 5-yr age cohort, females (000s)

Table 50. China prevalence of venous thromboembolism by 5-yr age cohort, males (000s)

Table 51. China prevalence of venous thromboembolism by 5-yr age cohort, females (000s)

Table 52. South Korea prevalence of venous thromboembolism by 5-yr age cohort, males (000s)

Table 53. South Korea prevalence of venous thromboembolism by 5-yr age cohort, females (000s)

Table 54. India prevalence of venous thromboembolism by 5-yr age cohort, males (000s)

Table 55. India prevalence of venous thromboembolism by 5-yr age cohort, females (000s)

Table 56. Australia prevalence of venous thromboembolism by 5-yr age cohort, males (000s)

Table 57. Australia prevalence of venous thromboembolism by 5-yr age cohort, females (000s)

Table 58. Brazil prevalence of venous thromboembolism by 5-yr age cohort, males (000s)

Table 59. Brazil prevalence of venous thromboembolism by 5-yr age cohort, females (000s)

Table 60. Mexico prevalence of venous thromboembolism by 5-yr age cohort, males (000s)

Table 61. Mexico prevalence of venous thromboembolism by 5-yr age cohort, females (000s)

Table 62. Argentina prevalence of venous thromboembolism by 5-yr age cohort, males (000s)

Table 63. Argentina prevalence of venous thromboembolism by 5-yr age cohort, females (000s)

## I would like to order

Product name: Epiomic Epidemiology Series: Venous Thromboembolism Forecast in 24 Major Markets 2018–2028

Product link: <https://marketpublishers.com/r/EFF9BFB7DC8EN.html>

Price: US\$ 5,800.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/EFF9BFB7DC8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



